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OBJECTIVE: To study the importance of NB84, synaptophysin and AgNOR and explore the quantitative association of these
factors with diagnosis and outcome as well as the association between NB84 and AgNOR and other tumor and stromal factors in
twenty-eight peripheral neuroblastic tumors.
METHODS: We assessed AgNORs, NB84, synaptophysin and several other markers in tumor tissues from 28 patients with
primary neuroblastic tumors. The treatment included: surgery for stage 1, chemotherapy and bone marrow transplantation for
most of stages 3 and 4. Histochemistry, immunohistochemistry and morphometry were used to evaluate the amount of tumor
staining for AgNOR, NB84 and synaptophysin; the outcome for our study was survival time until death due to recurrent neuroblastic
tumors.
RESULTS: Only stage (p<0.01), AgNOR (p<0.01), NB84 (p<0.01) and synaptophysin (p=0.01) reached statistical significance
as prognostic indicators.
CONCLUSIONS: Determination of NB84 and synaptophysin are useful tools for the diagnosis of peripheral neuroblastic tumors
The association of the evaluation of AgNOR expression by the tumor cells may provide an important contribution to the prognostic
evaluation and management approach of the patients.
KEYWORDS: Neuroblastoma. AgNOR. DNA ploidy. NB84. Synaptophysin
INTRODUCTION
Peripheral neuroblastic tumors (pNTs) are a heteroge-
neous group of tumors that do not have a simple and re-
producible morphological diagnosis and of which progno-
sis is variable, mainly due to the following features: a) pNTs
can arise in the adrenal medulla, sympathetic ganglia, and
sympathetic paraganglia; b) these tumors exhibit complex
histological findings; c) they do not have uniform termi-
nology and criteria for the designation of types and
subtypes and d) they are often diagnosed on the basis of a
biopsy sample from the primary tumor or from a metastatic
site, in which only a small portion of the tumor is avail-
able for the histological examination. Furthermore, to ex-
plain the biological relevance of the morphologic classifi-
cation, pathologists now have to associate prognostic mark-
ers to the histological examination to better identify pa-
tients that will be assigned to different therapeutic
protocols. Classical prognostic indicators such as age,1,-4
histological category or the International Neuroblastoma
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Pathology Committee5,6 Prognostic Group (INPC) are usu-
ally applied to large series of patients. Additionally, the cri-
teria proposed by the INPC5,6 are only applicable when the
entire or at least the major portion of the primary tumor is
excised. However, sometimes the pNTs have already
metastasized at the clinical presentation or the tumor can-
not be surgically excised. In these cases, one may decide
to perform only a biopsy from the primary tumor or from
the metastasis (lymph node, liver, skin, bone marrow, or
rarely, other sites) to attain the diagnosis. If the biopsy
specimen is inadequate for the classification of the tumor
type or subtype, tumor markers must be associated to the
histological evaluation. At the histological examination,
pNTs basically consist of small round cells, scattered
around the loose stroma, the neuropil. The small round cell
component frequently requires a differential diagnosis with
lymphoma, Ewing’s sarcoma and embryonal rhabdomyosa-
rcoma, among others. Therefore, there is great interest in
finding ways to identify which tumors are likely to recur
and shorten survival, mainly in small series of patients.
In this regard, many authors have studied biological and
diagnostic markers in tumors to discover which of these
markers might be related to tumor diagnosis, recurrence and
shortened survival. Because the monoclonal antibody NB84
directed to an unknown molecule of 57 kDa can provide
considerable assistance in the recognition of the neuroblastic
differentiation, NB84 has been thought to be important as
an adjuvant to the diagnosis in the routinely processed
specimens.7-9 In addition, as the nuclear and stromal activ-
ity of tumor cells have been shown to influence tumor in-
vasion and metastases, specific markers such as AgNOR,10-12
DNA ploidy, 13-15 Ki-67, 16,17 p53, 15,16,18 collagen and neuropil
matrix components have also been targeted as potential use-
ful tumor markers.16,19-22
To validate the importance of NB84, synaptophysin and
AgNOR and to explore the quantitative relationship be-
tween these factors and histological diagnosis and progno-
sis, as well as the relationship between NB84, synapto-
physin and AgNOR and other tumor and stromal factors,
we studied these markers in peripheral neuroblastic tumors
and herein report our results.
MATERIAL AND METHODS
Peripheral Neuroblastic Tumors (pNTs)
Out of 300 NTs diagnosed from 1992 to 2002, a total
of 28 cases from the Surgical Pathology Archives were in-
cluded in this study (Table 1). The inclusion criteria com-
prised the following conditions: 1) specimen obtained by
biopsy or surgical resection from the primary tumor; 2) no
chemotherapy or radiotherapy treatment prior to the diag-
nosis; 3) sufficient amount of tissue in the paraffin blocks
to perform serial sections for histochemical and immuno-
histochemical preparations and more than 10 medium-
power (100·) fields of adequate tissue for microscopic evalu-
ation; and 4) medical records with adequate information.
Small incisional biopsies from the primary or a metastatic
site, possibly not representative of the tumor, were excluded
from the study. Clinical staging was performed according
to the revised International Neuroblastoma Staging System
(INSS) criteria.23,24 Treatment included surgery for stage 1
(except for patient 13, who also received chemotherapy),
chemotherapy and bone marrow transplantation for most
of stages 3, 4; patient 4S received chemotherapy as well as
undergoing surgery. All cases were reviewed and the clas-
sification according to the INPC system was applied.5,6 The
following histological categories were defined: a) undiffer-
entiated neuroblastoma (Figure 1A), undifferentiated pleo-
morphic neuroblastoma, poorly differentiated neuroblas-
toma (Figure 1B) and differentiated neuroblastoma (Fig-
ure 1C); b) atypical nodular ganglioneuroblastoma, inter-
mixed ganglioneuroblastoma (Figure 1D) and classical
nodular ganglioneuroblastoma and c) maturing ganglioneu-
roma and mature ganglioneuroma. The histopathological
classification and the staging data are shown in Table 1.
The clinical records were reviewed for data concerning the
relapse-free intervals and overall survival (Table 1).
Morphological Study
Immunohistochemistry
After surgical resection or biopsy, the tissue was forma-
lin-fixed in 10% neutral-buffered formalin and processed
for routine histological analysis. The expression of p53, Ki-
67, NB84 and synaptophysin was evaluated by immunohis-
tochemistry, using the avidin-biotin immunoperoxidase
technique. The antibodies used were: NCL-NB84
monoclonal mouse (clone NB84a; dilution of 1:400;
Novocastra Laboratories – Newcastle, UK); monoclonal
mouse antihuman directed to p53 protein (dilution of 1:100;
Dako A/S, Glostrup-Denmark); monoclonal antibody di-
rected to Ki-67 antigen (MIB-1; dilution of 1:100;
Immunotech, Marseille – France) and monoclonal antibody
to synaptophysin (363 M; dilution of 1:400; BioGenex, CA-
USA). Brownish nuclear, membrane or cytoplasmic stain-
ing was considered to be evidence of the antigen expres-
sion by the cells, according to Ki-67 (Figure 1E, 1F), p53
(Figure 1G), NB84 (Figure 1H) and synaptophysin expres-
sion (Figure 1I), respectively. The positive index for each
antibody was systematically determined in the “hot spot”
areas.25 The counting of positive cells was performed for
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Ki-67, p53 and NB84 at a magnification of X1000 in
noncoincident microscopic fields, counting a total of 1,000
tumor cells. The results were expressed as the index of posi-
tive cells. Synaptophysin was quantified in an image
analyzer system. The positive areas occupied by this struc-
ture within a known tumor area were expressed in square
micrometers (mm2).
AgNOR. Slides for AgNOR evaluation were stained
with the modified one-step silver colloid method26 in 3-mm
thick sections. A total of 100 cells per case were analyzed
at a 1000x magnification and the results were expressed
in terms of mean area (mm2) occupied by the dark dots in-
side the nucleus of the tumor cells (Figure 1J).
Extracellular Matrix. Collagen fibers were stained with
a 0.2% Sirius red solution (Direct Red 80, CI 35780,
Aldrich, Milwaukee, WI) dissolved in aqueous saturated
picric acid solution. This staining method has been used
since 1964 for collagen staining in histological specimens.
The enhancement of collagen birefringence promoted by
the picrosirius polarization method is specific for collagen-
ous structures consisting of aggregates of orientated mol-
ecules.27-29 Five different fields were randomly selected and
the density of collagen fibers was quantified at a magnifi-
cation of x200, using an image analysis system (software
Bioscan-Optimas 5.1, Bioscan Inc; Edmonds, Wash). The
threshold for collagen was selected for individual cases, af-
ter enhancing the contrast up to a point at which the fibers
were easily identified. The amount of collagen fibers was
expressed in square micrometers (Figure 1K, 1L).
DNA. Tissue sections were treated with 5N hydrochlo-
ric acid for 60 min at room temperature and then stained
with the DNA Feulgen staining (Tripath Imaging Inc, Feul-
gen Biological Stain Kit, Auto Cyte – TI, Inc Burlington,
NC, USA), Slides containing pellets of diploid and tetra-
ploid hepatocytes (Cell Analysis Systems) were used as con-
trols. Following dehydration with ethyl alcohol and clear-
ing in xylene, the slides were coverslipped with Entellan
(MERCK®). The evaluation of the nuclear DNA was per-
formed in a digital image analyzer, using the CAS – “Quan-
titative DNA analysis” software (version 3.0). Control cells
with a known DNA content (tetraploid rat hepatocytes)
Table 1 - Clinicopathologic data
Abbreviations: Recur (recurrence, 1 yes, 2 no), death (1 yes, 2 no), surv (survival); NR=never remitted; Histol. Categ.= histological categories: 1=
neuroblastoma and 2=ganglioneuroblastoma. INPC PG = International Neuroblastoma Pathology Classification Prognostic Groups: FH = Favorable
histology; UH= Unfavorable histology and UC= Unclassifiable; mo = months; synapt = synaptophysin
Case
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Age (mo)
52
20
50
48
73
32
8
12
5
1
16
51
9
11
41
48
72
4
60
78
13
8
15
14
29
14
69
36
Stage
1
1
4
4
4
1
3
4
4S
3
1
3
1
3
4
4
4
4
4
4
1
1
3
1
3
3
4
1
Recur
No
No
Yes
NR
NR
No
No
No
No
No
No
Yes
Yes
No
Yes
NR
Yes
Yes
Yes
NR
No
No
Yes
No
No
Yes
No
No
Death
No
No
No
Yes
Yes
No
No
Yes
No
No
No
No
No
No
Yes
Yes
No
No
No
Yes
No
No
No
No
No
Yes
No
No
Overall
Surv
(mo)
108
104
97
11
16
74
58
16
52
49
47
50
39
37
29
10
33
29
44
14
23
20
16
13
118
92
87
80
Histol.
Categ.
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
2
1
2
INPC
PG
FH
UH
UH
UH
UH
FH
UH
FH
FH
FH
UH
UC
FH
FH
UC
UH
UC
UH
FH
UH
FH
FH
FH
FH
UH
FH
UH
FH
AgNOR
(mm2)
6.87
5.68
6.71
6.53
5.67
10.53
5.22
6.05
4.66
9.60
4.41
4.79
5.03
5.57
7.68
4.91
2.78
-
3.97
4.23
4.32
4.30
5.03
5.25
4.39
5.03
3.49
6.81
Ki-67 n/
1000
7
130
0
23
122
103
403
127
35
353
211
28
210
260
5
40
255
254
4
225
339
347
214
73
297
248
89
5
p53 n/
1000
0
0
0
0
0
0
0
0
0
10
0
0
0
1
0
0
0
6
28
0
0
2
3
4
0
0
0
0
NB84 n/
1000
180
35
3
0
383
272
0
0
268
420
220
18
603
313
468
9
229
205
165
147
0
324
313
386
369
492
0
9
Synapt
(mm2)
39815.29
765.75
404.13
2095.73
6070.45
12943.75
2050.51
839.21
1056.62
9024.27
7815.42
386.07
208.99
736.82
16654.60
11377.19
605.37
2124.92
18863.18
2063.27
31.23
4881.43
15482.28
848.45
2981.25
6841.63
1940.79
26602.42
Collagen
(mm2)
9536.90
1788.97
5692.26
707.90
3600.20
4960.87
4667.15
16225.63
4443.08
24462.83
5911.57
12161.41
9290.43
3054.31
20694.24
17582.63
35526.60
4947.70
100449.88
47493.83
13733.51
27382.86
11403.13
2989.12
5321.41
37157.51
10429.07
20966.24
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were analyzed to determine the optical density of each
slide, allowing the system calibration (external control).
DNA from endothelial cells present in all specimens was
measured separately and was used as the internal control.
The DNA content of 200 tumor cells from every slide was
analyzed. A frequency histogram using cell count vs. DNA
content was generated. The results were expressed as DNA
index (ID), and the tumor cells were classified as: diploid
(ID: 0.8 – 1.2); tetraploid (ID: 1.8 – 2.2) and aneuploid
for the other indexes.16
Statistical Analysis
The association between age, tumor stage, histological
categories, INPC Prognostic Group, AgNOR, Ki-67, p53,
NB84, DNA, collagen and synaptophysin was verified in
subgroups of patients stratified by tumor recurrence using
Fisher’s exact test. For this analysis, AgNOR, Ki-67, p53,
NB84, collagen and synaptophysin were dichotomized at
the median. When applying the INPC pattern for age dis-
tribution, three groups were obtained: <18 months, 18 to
60 and > 60 months. Survival was illustrated by Kaplan-
Meier curves. Cox regression analysis was used to exam-
ine the relationship between pathological variables and
mortality, controlling for other potential confounders includ-
ing patients’ age, stage, histological categories and INPC
Prognostic Group. The impact of AgNOR was verified re-
garding survival time and recurrence, added as covariable
dichotomized at the median (low and high) and as a con-
tinuous covariable. All statistical analyses were performed
using the SPSS software program (SPSS Inc., Chicago, IL,
version 9.0). The statistical significance was set at p< 0.05.
RESULTS
The patients’ ages at diagnosis ranged from 1 to 78
months (Table 1); thirteen (13) patients presented age < 18
months (46.4%), 11 (39.2%) patients presented age from
18 to 60 months and 4 (14.2%) patients presented age >
60 months. No statistical difference was found between age
and tumor recurrence (p=0.2) (Table 2; Figure 2A). For
clinical stage 9 patients were at stage I; 7 patients at stage
3; 11 patients at stage 4 and only one patient at stage 4S
(Table 1). Of the patients at stages 1, 3 and 4S disease (17
pts, 7%) only 4 patients (14.3%) presented disease recur-
rence. However, of the 11 patients (39.2%) at advanced
stage (4), 9 (32.1%) presented recurrence, which showed
statistical significance (p=0.01) when compared to the stage
1, 3 and 4S patients. Histological categories included 24
cases of neuroblastomas and 4 cases of ganglioneu-
roblastomas. INPC Prognostic Groups included 14 cases of
Figure 1 (Panels A to L). (A) Undifferentiating neuroblastoma: note hormer-
wright rosettes (arrows; H&E X400); (B) Poorly differentiated neuroblastoma
(H&E X400); (C) Differentiating neuroblastoma (H&E X400); (D) Intermixed
ganglioneuroblastoma (H&E, X400); (E) “Hot spot” in a case of poorly
differentiated neuroblastoma, immunostained for Ki-67/MIB-1
(immunohistochemistry X400); (F) Ki-67/MIB-1 expression (stained brown)
in a case of undifferentiated neuroblastoma (immunohistochemistry X400);
(G) P53 expression (arrows) in a case of undifferentiated neuroblastoma
(immunohistochemistry X400); (H) NB84 expression (stained brown) in a
case of poorly differentiated neuroblastoma (oimmunohistochemistry X400);
(I) Synaptophysin expression in a case of differentiated neuroblastoma: note
synaptophysin-positive Schwann cells (stained brown) in the stromal septa,
demarcating neuroblastic lobules (immunohistochemistry X400); (J)
Undifferentiated neuroblastoma stained for “dots” of AgNOR (arrows); (K, L)
Differentiated neuroblastoma stained for Picro-sirius (X400).
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favorable histology, 11 cases of unfavorable histology and
3 cases were unclassifiable (Table 1). In this study, histo-
logical categories and INPC prognostic groups classifica-
tion did no present statistical association with tumor recur-
rence. Eleven cases (40.7%) presented high expression of
AgNOR (5.0 mm2) associated to tumor recurrence, whereas
12 cases (44.4%) presented low expression of this marker
(0.6 mm2) without tumor recurrence, with a statistically sig-
nificant difference (p<0.01; Table 2, Figure 2B). Equally
significant was the higher expression of NB84 (217/1000)
in 12 (42.9%) cases with disease recurrence compared to
low expression (20/1000) in 13 (46.4 %) cases without re-
currence (p<0.01; Table 2, Figure 2C). A significant dif-
ference (p= 0.008) was found between the low amount
(505.6 mm2) of synaptophysin found in 10 cases (35.7%)
with tumor recurrence and the high expression (7591.8
mm2) of this neuroendocrine marker detected in 11 cases
(39.3%) without tumor recurrence (Table 2, Figure 2D).
Difference between the high amount of collagen (16904.1
mm2) found in 9 (32.1%) cases with tumor recurrence and
the low amount (3227.2 mm2) present in 10 (35.7 %) cases
without tumor recurrence attained marginal significance
(p=0.06, Table 2). No statistical difference was found for
the low and high expressions of Ki67, p53, DNA Ploidy
and presence or absence of tumor recurrence.
Table 2 - Differences in the frequency of clinical and of morphological variables (threshold: low and high) in subgroups of
patients stratified by tumour recurrence.
Abbreviations: INPC – International Neuroblastoma Pathology Classification
Variables
Age (months)
0 a <18
18 a 60
> 60
Stage
1
3
4
4S
Histologic Category
neuroblastoma
ganglioneuroblastoma
INPC Prognostic Groups
Favorable Histology
Unfavorable Histology
AgNOR
0.6 mm2
5.0 mm2
Ki67
34.8  / 1000
236.5 / 1000
p53
0 / 1000
4/ 1000
NB84
20/1000
217/1000
DNA Ploidy
tetraploid
diploid
aneuploid
Synaptophysin
505.6 mm2
7591.8 mm2
Collagen
3227.2 mm2
16904.1 mm2
Positive
4 (14.3%)
6 (21.4%)
3 (10.7%)
1 (3.6 %)
3 (10.7 %)
9 (32.1 %)
0
11 (39.3 %)
2 (7.1 %)
4 (16 %)
6 (24 %)
1 (3.7 %)
11 (40.7%)
6 (21.4 %)
7 (25.0 %)
10 (35.7 %)
3 (10.7 %)
1 (3.6 %)
12 (42.9%)
1 (3.6 %)
1 (3.6 %)
11 (40.7%)
10 (35.7 %)
3 (10.7 %)
4 (14.3%)
9 (32.1%)
 Negative
9 (32.1%)
5 (17.9%)
1 (3.6%)
8 (28.6 %)
 4 (14.3 %)
2 (7.1 %)
1 (3.6 %)
13 (46.4 %)
2 (7.1 %)
10 (40 %)
   5 (20 %)
12 (44.4%)
3 (11.1%)
       8 (28.6%)
7 (25.0 %)
11 (39.3 %)
4 (14.3 %)
13 (46.4 %)
2 (7.1 %)
5 (17.9 %)
1 (3. 6%)
10 (32.1 %)
4 (14.3 %)
11 (39.3 %)
10 (35.7 %)
5 (17.9%)
p value
0.2
0.01
0.8
0.1
0.0001
0.7
0.8
0.0001
0.2
0.008
0.06
Tumour Recurrence
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Survival Time Analysis
The preliminary examination of the Kaplan-Meier sur-
vival curves (data not shown) demonstrated that, in this
study, only patients with pathological stages 3 and 4 had
different hazards for survival, with a median time of 92 and
29 months for each group, respectively (Figure 2E). The
results of the Cox model are shown in Table 3. Two vari-
ables were significantly associated with survival time:
pathological stage and AgNOR expression. We observed
that stage was significantly related to survival time and re-
currence, even when the AgNOR expression was not con-
sidered (p = 0.004 and 0.003, respectively). However, when
AgNOR was added as a covariable, its association with sur-
vival and tumor recurrence was much stronger. The over-
all likelihood ratio (survival vs recurrence) using only tumor
stage was 29.71 and 60.0, respectively. When the AgNOR
expression was associated (cutoff of 5.0 m2) to the stage,
the likelihood ratio for survival and recurrence changed to
38.13 and 65.9, respectively. We also observe that the prog-
nostic information provided by the AgNOR estimation was
maximized when this parameter was used as a continuous
variable, that is, without using a cutoff level (41.65 and
65.58, respectively). The association between survival time
and AgNOR expression is illustrated by the plots in Fig-
ure 2. The group with AgNOR < 5 mm2 appears in the up-
per curve. Their median survival time was not reached dur-
ing the follow-up period of observation, but it was quite
long, at 100.33 months. On the other hand, the cases that
presented AgNOR> 5 mm2 (lower curve) had a median sur-
vival time of only 92 months (p=0.05 by log rank test). Fig-
ures 2G and 2H we present the cumulative hazard curves
for recurrence, according to stage (log rank test 11.8; p =
0.008) and AgNOR as a continuous variable (log rank test
67.2; p < 0.001).
DISCUSSION
The majority of the small blue round-cell tumors can
be diagnosed by the conventional histological analysis.
However, diagnostic difficulties are often observed with the
less differentiated ones, which show no neural, rhabdoid or
epithelial differentiation at light microscopy. Immunohis-
tochemistry has proved to be a useful adjunctive method
for the differential diagnosis of these tumors.7,8,23 This is
particularly true for the identification of lymphomas and
leukemia, which are the most frequent members of this
group of tumors. However, the diagnosis of neuroblastomas
is more complex. There are only a few available monoclonal
Table 3 - Cox Proportional Hazard Model Analysis of
Survival Timei ando Recurrence
Variable Coefficient SE Likelihood ratio P value
Stage -2.47 – 11.59 1.08 – 0.60 29.71 – 60.0 0.004 – 0.003
AgNOR 1.07 – 2.38 1.08 – 1.04 38.13 – 65.9 0.07 – 0.004
Stage AgNOR -2.26 - -0.94 1.15 – 0.63 32.48 0.008
0.76 – 1.94 1.14 – 1.08 53.60 0.003
AgNOR 41.65 – 65.58 0.00001 –
0.00001
Figure 2 (Panels A to H) - Graphics illustrating differences in the frequency
of clinical and morphological variables in subgroups of patients stratified
by tumour recurrence (Panels A to D). In panel E is shown the survival plot
by stage in patients with NTs. In panel F is shown the survival plot by
positivity for AgNORs (high and low valours). In panels G and H the risk
plot by stage and positivity for AgNORs, respectively).
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antibodies with reactivity against these tumors cells and
these antibodies present variable and limited specificity and
sensitivity for the routinely processed material.8
In this study, we tested the monoclonal antibody NB84,
which showed immunoreactivity in approximately 90% of
the tumors. Similar results were obtained by Thomas and
coleagues8, who observed reliable staining of 17/19 (90%)
neuroblastomas, which was negative for all other tumors
except for Ewing’s sarcomas, of which 9/14 (64%) showed
mainly focal positivity. This finding suggests that NB84
provides considerable assistance in the recognition of neu-
roblastomas and thus it is important to allow the most ap-
propriate therapy to be established. Furthermore, we found
a higher number of NB84 positive cells in the group of pa-
tients that presented tumor recurrence, the majority of them
undifferentiated or poorly differentiated neuroblastomas,
once more showing that NB84 can be used to predict the
behavior of these tumors. Compared to NB84, we found that
synaptophysin, a neuroendocrine marker of well differen-
tiated cells, was positive in 100% of the cases and highly
expressed by tumors without potential for recurrence, mak-
ing synaptophysin a potential marker to predict tumor
behavior. Similar findings were also observed by Miettinen7
and Bozzi.30
 For clinical and pathological use, it would be desirable
that the aforementioned adjuvant methods could also pro-
vide information related to tumor prognosis, in addition to
being easy to perform as well as rapidly assessable and re-
producible.9 Considering the large variety of tumors and the
diversity of their biological behaviors, there is no univer-
sal marker that fulfills all these conditions. A variety of new
markers has been proposed to aid in the diagnosis of some
tumor types and to better evaluate the prognosis of these
tumors. Recently, the quantitation of interphasic NORs has
been associated with growth rate in neuroblastoma cell
lines.11 A decreasing number of nucleolar organizer regions
was found to be associated with histopathological grades,
high nerve growth factor receptor (TRKA) expression and
a better survival.12 Addditionally, stage IVS patients, lymph
nodes and distant metastasis exhibited reduced nucleolar
organizing region counts when compared with stage IV.10
Therefore, for all these reasons, we should not be surprised
at the fact that that staining for AgNOR provides impor-
tant prognostic information about pNTs and our results have
now confirmed the prognostic importance of AgNOR in
pNTs. Whereas only three prior studies were able to show
a significant association between staining for AgNOR in
the tumor and survival10-12 our results suggest that staining
for AgNOR, used as a continuous variable, provides more
prognostic information than the routine pathological stag-
ing. Although we were unable to identify a binary cutpoint
in AgNOR, a natural dividing point was the median of 5.0
mm2 of nucleoli area expressing AgNOR and this point pro-
vided a practical means to separate them into two groups:
patients with an expected short survival versus patients with
an expected longer survival. Thus, staining of the pNTs for
AgNOR offers us the potential to offer the use of adjuvant
chemotherapy in patients likely to recur after the surgical
excision of pNTs. In summary, to reach this conclusion will
require a larger study in a randomized and prospective trial
and we also believe it is important to validate our quanti-
tative assessment of AgNOR in additional pNTs.
 Among the microenvironmental features, the extracel-
lular matrix components (collagen density) seems to be an
important prognostic parameter, mainly in some special
cancer types16,19. Although several studies of extracellular
matrix proliferation in cancer have been carried out 20,21 the
association of these parameters with nuclear changes and
oncogenic characteristics in pNTs, as well as the impact of
these factors on prognosis have not been previously con-
sidered. Although with marginal significance, our data
showed that tumors with higher collagen density were at
an upper risk for recurrence. The extracellular matrix is an
important, although poorly understood, collagenous host
response to tumor invasion22. Shimosato et al19 reported one
of the first studies about the impact of the extracellular ma-
trix proliferation on cancer prognosis. They showed that
tumors with a rich extracellular matrix tend to present
higher blood vessel invasion and a greater incidence of
lymph node metastasis, carrying a poor prognosis when
compared to cases with low or no extracellular matrix pro-
liferation. Regardless of the mechanism, the quantification
of collagen can also provide prognostic information in
pNTs. Other classic markers investigated in our study were
Ki-67,17 p5315,18 and DNA ploidy,13,14,23 which did not show
association with NTs prognosis.
Finally, we should explain the negative results of classi-
cal prognostic indicators such as age,1-4 histological category
or INPC Prognostic Group5,6 in our series. Based on the lit-
erature and the recent published article by Sano and col-
leagues,31 the International neuroblastoma pathology classi-
fication adds independent prognostic information beyond the
prognostic contribution of age. Age has been used as a prog-
nostic factor for patients with peripheral neuroblastic tumors
(pNTs). According to these authors, the analysis disclosed a
cutoff of around 18 months for the optimal prognostic dis-
tinction. The International Neuroblastoma Pathology Clas-
sification (INPC) differentiates favorable from unfavorable
histology based on the age-appropriate evaluation of histo-
logical indicators (grade of neuroblastic differentiation, mi-
tosis-karyorrhexis index) in the categories of nodular neu-
roblastomas and ganglioneuroblastomas. Sano´s study31
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showed that age, which was tested by using 3 different cut-
offs (12, 18 and 24 months), was prognostically significant.
INPC remained prognostically significant regardless of the
age group to which it was applied. Prognostic effects of age
and histological indicators were independently significant,
i.e., age had a prognostic capacity beyond that of histologi-
cal indicators, and histological indicators had a prognostic
capacity beyond that of age. Due to the fact that INPC in-
corporated the age factor (18, 60 months) into the system,
it was better than age alone for the prognostic differentia-
tion of pNT patients. Based on the literature and the recent
published article by Sano and colleagues, who studied a se-
ries of 911 patients, the INPC adds independent prognostic
information beyond the prognostic contribution of age. The
great series of patients studied by these authors allow to bet-
ter understand the definite role of classical prognostic indi-
cators such as age, histological category and INPC. Prog-
nostic Group and probably explains our negative findings.31
Despite the limitations observed in a small series of pa-
tients, we concluded that the determination of NB84 and
synaptophysin are useful tools for the histological diagno-
sis of pNTs. When these markers are associated with the
evaluation of the AgNOR expression by the tumor cells,
they provide an important contribution to the prognostic
evaluation and management approach of patients with
pNTs. Further studies with a larger number of cases should
be developed to assess the real value of the associated
quantitation of NB84 and synaptophysin to the AgNOR ex-
pression for better diagnosis and prognosis attainment in
patients with peripheral neuroblastic tumors.
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RESUMO
Carvalho AC, Parra ER, Zerbini MC, Alves VAF, Capelozzi
VL, Antonangelo L. A avaliação morfométrica de NB84,
sinaptofisina e AgNOR é útil para o dignóstico histológico
e prognóstico dos tumores neuroblásticos periféricos
(pNTs). Clinics. 2007;62(6):731-40.
OBJETIVO: Estudar a importância dos marcadores NB84
e AgNOR e explorar as relações quantitativas entre esses
marcadores com o diagnóstico e prognóstico assim como
as relações entre NB84 e AgNOR e outros marcadores
tumorais e estromais em 28 tumores neuroblásticos
periféricos.
MÉTODOS. Examinamos AgNOR, NB84 e sinaptofisina
e vários outros marcadores em tecidos tumorais de vinte e
oito pacientes com tumors neuroblásticos primários.
Tratamento dos pacientes incluiu: cirurgia para o estágio
1, quimioterapia e transplante de medula óssea para a
maioria dos pacientes nos estágios 3 e 4. Utilizamos
739
CLINICS 2007;62(6):731-40 Morphometric evaluation of nb84, synaptophysin and AgNOR is useful for the histological diagnosis
Carvalho AC et al.
histoquímica, imunohistoquímica e morfometria para
avaliar a intensidade e extensão de expressão do AgNOR,
NB84 e sinaptofisina, tendo o prognóstico dos pacientes
incluído o tempo de sobrevida até a morte por recurrência
dos tumores neuroblásticos.
RESULTADOS. Estadiamento (p<0.01), AgNOR (p<0.01),
NB84 (p<0.01) e sinaptofisina (p=0.01) foram marcadores
independents de sobrevida.
CONCLUSÕES. A determinação dos marcadores NB84 e
sinaptofisina mostrou-se como uma ferramenta útil no
diagnóstico dos tumors neuroblásticos periféricos; a
associação desses marcadores à expressão de AgNOR pelas
células tumorais contribuiu à determinação do prognóstico
e estabelecimento do protocolo terapêutico para os
pacientes.
UNITERMOS: Neuroblastoma. Prognóstico. AgNOR.
Ploidia de DNA. NB84. Sinaptofisina.
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